Regenerative Medical Technology (RMTG) EV to EBITDA (2018 - 2026)

Regenerative Medical Technology has reported EV to EBITDA for 9 years, with the latest figure at 1.01 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 119.86% year-over-year to 1.01 in Q2 2026; TTM through Jun 2026 was 2.06, a 34.27% increase from a year earlier, with the FY2025 full-year figure at 0.44, up 111.34% from the prior year.
• EV to EBITDA was 1.01 for Q2 2026 at Regenerative Medical Technology, up from 2.2 in the prior quarter.
• The five-year high for EV to EBITDA was 33.07 in Q1 2023, with the low at 42.51 in Q3 2023.
• Average EV to EBITDA over 5 years is 0.68, with a median of 1.2 recorded in 2025.
• The largest YoY upside for EV to EBITDA was 1062.37% in 2023 against a maximum downside of 469.84% in 2023.
• Over 5 years, EV to EBITDA stood at 0.56 in 2022, then soared by 1062.37% to 6.48 in 2023, then tumbled by 137.09% to 2.4 in 2024, then surged by 153.67% to 1.29 in 2025, then sank by 177.98% to 1.01 in 2026.
• The last three EV to EBITDA figures came in at 1.01 (Q2 2026), 2.2 (Q1 2026), and 1.29 (Q4 2025), per Business Quant data.